A study to evaluate the efficacy and safety of Obefazimod (ABX464) in patients with moderate to severe active ulcerative colitis (UC) taking Obefazimod or placebo once daily.
Résumé de l'étude
Obefazimod is a novel, orally administered anti-inflammatory drug candidate that specifically increases the production of a molecule called miR-124, which is produced naturally by the human body and has anti-inflammatory properties. Clinical experiences gained during the development phase of Obefazimod with doses of 25 mg and 50 mg showed relevant efficacy with a favorable short- and long-term safety profile. This study is part of a global Phase III study program consisting of two similar 8-week induction studies (ABX464-105 and ABX464-106), followed by a 44-week maintenance study (ABX464-107). The maintenance study will be offered to all eligible and willing participants from both induction studies. Approximately 1224 patients (612 per induction study) will be enrolled in this program and followed up in 36 countries worldwide. Switzerland will participate in ABX464-105, followed by ABX464-107, and about 10 patients will be enrolled in the study there.
(BASEC)
Intervention étudiée
This study will consist of 3 treatment groups, in which 2 doses of Obefazimod and a placebo will be compared (a placebo looks the same as Obefazimod but contains no active ingredient). Participants will be randomly assigned to one of three treatment groups, with a 75% chance of receiving Obefazimod and a 25% chance of receiving the placebo. The study drug will be provided in the form of a capsule (in blister packs) to be taken orally once daily.
This study consists of three phases: a pre-screening phase of up to 28 days to check the eligibility of patients, an 8-week treatment phase, and a 28-day follow-up phase.
Eligible patients will undergo the following examinations as part of the study:
- physical examinations
- electronic diaries and questionnaires (on an electronic device)
- colonoscopies (videos from inside the intestine) with biopsies (small samples from the intestinal wall)
- blood draws
- electrocardiograms
- eye examinations
(BASEC)
Maladie en cours d'investigation
Ulcerative colitis (UC) is part of the group of inflammatory bowel diseases (IBD), characterized by a misregulated immune response associated with chronic inflammation in the gastrointestinal tract, affecting the rectum and colon. The cause of UC is unknown, but it is believed that genetic, environmental, and immunological factors contribute to its development. UC is typically diagnosed at the end of adolescence/early adulthood. Quality of life is dramatically affected, ranging from direct physical disabilities to financial burdens. Among the global population suffering from UC, 66% report being affected at work and 73% in their leisure activities. More broadly, UC also burdens immediate family members and affects family quality of life. Most patients present with mild to moderate UC at diagnosis, but about one-third progress to moderate to severe UC. Conventional therapies such as 5-aminosalicylic acids (5-ASA), corticosteroids, and immunosuppressants have mostly been used to treat these patients. Since 2005, new advanced therapeutics known as biologics have been approved for the treatment of UC. Biologics are produced using biotechnological methods and block certain parts of the immune system, such as pro-inflammatory proteins (e.g., TNF inhibitors Infliximab, Adalimumab, and Golimumab, integrin antagonists like Vedolizumab, and also IL 23 inhibitors like Ustekinumab) and more recently JAK inhibitors (e.g., Tofacitinib, Filgotinib, Upadacitinib) and S1P modulators (e.g., Ozanimod).
(BASEC)
The three most relevant inclusion criteria: - Men or women aged at least 16 years with a diagnosis of UC confirmed by colonoscopy and histology prior to the pre-screening date. - Patients must have moderate to severe active disease. Additionally, patients must have demonstrably inadequate responses to at least one of the following treatments (e.g., lack of response, loss of response, or intolerance): corticosteroids, immunosuppressants, biological therapies, S1P receptor modulators and/or JAK inhibitors and/or newly approved medications. - Female patients and partners of male patients who can become pregnant must agree to use either two highly effective methods or one highly effective method in combination with one effective method of contraception during the study and for at least 21 days after the last dose of the study drug. Male participants must use a condom for all sexual relations during the entire treatment period of the study and for 21 days after the last dose of the study drug. (BASEC)
Critères d'exclusion
The three most relevant exclusion criteria: - Other gastrointestinal diseases, such as UC, limited to isolated proctitis (when the mucosal tissue of the inner rectum becomes inflamed), primary sclerosing cholangitis (a disease that destroys the bile ducts) or autoimmune hepatitis (a chronic disease in which the immune system attacks healthy, normal liver cells), Crohn's disease (CD) or inflammation of the colon. - History or active cancer (expected if the disease has not been active for at least 5 years). - Pregnant or breastfeeding women or women who can become pregnant and plan to become pregnant during the study duration, as well as male patients with a partner who can become pregnant and plans to become pregnant during the study duration. (BASEC)
Lieu de l’étude
Bâle, Berne, Zurich
(BASEC)
Sponsor
ABIVAX S.A., Paris, France IQVIA AG, Branch Basel, Basel
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Luc Biedermann
+41 44 255 85 48
luc.biedermann@clutterusz.chUniversitätsspital Zürich, Klinik für Gastroenterologie und Hepatologie, Rämistrasse 100, 8091 Zürich
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Berne
(BASEC)
Date d'approbation du comité d'éthique
13.07.2023
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible